An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies (2018–2024)

Grant type:
NHMRC MRFF - Lifting Clinical Trials Registries Capacity
Researchers:
Funded by:
Commonwealth Department of Health